EBIT at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's EBIT?
- 4D Molecular Therapeutics (FDMT) reported EBIT of -$73.62M in Q1 2026.
- How has 4D Molecular Therapeutics's EBIT changed year-over-year?
- 4D Molecular Therapeutics's EBIT decreased by 37.3% year-over-year, from -$53.62M to -$73.62M.
- What is the long-term trend for 4D Molecular Therapeutics's EBIT?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's EBIT has grown at a 25.0% compound annual growth rate (CAGR), from -$71.33M to -$174.26M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.